Targeted therapy in CLL
BTK and BCL2 inhibitors in chronic lymphocytic leukaemia.
Key point
In CLL/SLL, treatment selection is tailored based on age, genetic risk and comorbidities, prioritizing zanubrutinib, acalabrutinib and venetoclax-based regimens.
From: Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus (Clin Exp Med, 2026 Mar 7) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 30, 32, 33, 38, 39.
New guidelines and consensus this year
- Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateIntern Med J2026 Aug
- Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensusClin Exp Med2026 Mar 7
- Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panelFront Med (Lausanne)2025
All papers from the last 12 months
437 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case reportAm J Ophthalmol Case Rep2026 DecPMID 42740827
- Quality by design-based development of ibrutinib polymer-lipid hybrid nanoparticles for enhanced lymphatic absorption and anticancer efficacyInt J Pharm X2026 DecPMID 42436867
- Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regressionJ Med Econ2026 DecPMID 41553230
- A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaJ Med Econ2026 DecPMID 41454883
- Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemiaBlood Neoplasia2026 NovPMID 42733538
- Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL StudyAm J Hematol2026 NovPMID 42573556
- Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship PerspectiveEur J Haematol2026 NovPMID 42437563Review
- Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutationBlood Adv2026 Oct 16PMID 42887491
- Efficacy of continuous ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia with high-burden and low-burden TP53 mutations: Multicenter retrospective analysis of the Polish Adult Leukemia Group (PALG)Adv Clin Exp Med2026 Oct 15PMID 42878334
- Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemiaBlood Adv2026 Oct 13PMID 42498281
More hematology trends
All specialties →Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Paroxysmal nocturnal haemoglobinuria
PNH and new oral complement inhibitors.
Menin inhibitors in AML
Revumenib, ziftomenib and other menin inhibitors in acute leukaemia.
DOACs in heparin-induced thrombocytopenia
Studies of direct oral anticoagulants for the treatment of heparin-induced thrombocytopenia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("chronic lymphocytic leukemia"[tiab] OR "chronic lymphocytic leukaemia"[tiab] OR CLL[tiab]) AND (BTK[tiab] OR ibrutinib[tiab] OR acalabrutinib[tiab] OR zanubrutinib[tiab] OR pirtobrutinib[tiab] OR venetoclax[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.